Correlation Between Apellis Pharmaceuticals and Halozyme Therapeutics
Can any of the company-specific risk be diversified away by investing in both Apellis Pharmaceuticals and Halozyme Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Apellis Pharmaceuticals and Halozyme Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Apellis Pharmaceuticals and Halozyme Therapeutics, you can compare the effects of market volatilities on Apellis Pharmaceuticals and Halozyme Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Apellis Pharmaceuticals with a short position of Halozyme Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Apellis Pharmaceuticals and Halozyme Therapeutics.
Diversification Opportunities for Apellis Pharmaceuticals and Halozyme Therapeutics
0.63 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Apellis and Halozyme is 0.63. Overlapping area represents the amount of risk that can be diversified away by holding Apellis Pharmaceuticals and Halozyme Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Halozyme Therapeutics and Apellis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Apellis Pharmaceuticals are associated (or correlated) with Halozyme Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Halozyme Therapeutics has no effect on the direction of Apellis Pharmaceuticals i.e., Apellis Pharmaceuticals and Halozyme Therapeutics go up and down completely randomly.
Pair Corralation between Apellis Pharmaceuticals and Halozyme Therapeutics
Given the investment horizon of 90 days Apellis Pharmaceuticals is expected to under-perform the Halozyme Therapeutics. In addition to that, Apellis Pharmaceuticals is 1.09 times more volatile than Halozyme Therapeutics. It trades about -0.02 of its total potential returns per unit of risk. Halozyme Therapeutics is currently generating about 0.03 per unit of volatility. If you would invest 4,505 in Halozyme Therapeutics on August 31, 2024 and sell it today you would earn a total of 342.00 from holding Halozyme Therapeutics or generate 7.59% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Apellis Pharmaceuticals vs. Halozyme Therapeutics
Performance |
| Timeline |
| Apellis Pharmaceuticals |
| Halozyme Therapeutics |
Apellis Pharmaceuticals and Halozyme Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Apellis Pharmaceuticals and Halozyme Therapeutics
The main advantage of trading using opposite Apellis Pharmaceuticals and Halozyme Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Apellis Pharmaceuticals position performs unexpectedly, Halozyme Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Halozyme Therapeutics will offset losses from the drop in Halozyme Therapeutics' long position.| Apellis Pharmaceuticals vs. Cue Biopharma | Apellis Pharmaceuticals vs. Eliem Therapeutics | Apellis Pharmaceuticals vs. Inhibrx | Apellis Pharmaceuticals vs. Molecular Partners AG |
| Halozyme Therapeutics vs. Agios Pharm | Halozyme Therapeutics vs. Insmed Inc | Halozyme Therapeutics vs. Ultragenyx | Halozyme Therapeutics vs. Biomarin Pharmaceutical |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Complementary Tools
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |